Aspirin prevents platelet aggregation by inhibiting which enzyme?

Aspirin plays a crucial role in preventing platelet aggregation through the inhibition of cyclo-oxygenase (COX), an important enzyme in the arachidonic acid pathway responsible for the synthesis of thromboxane A2. Thromboxane A2 is a potent promoter of platelet activation and aggregation. By inhibiting COX, aspirin reduces the production of thromboxane A2, thereby leading to decreased platelet aggregation and a reduced risk of thrombus formation.

Additionally, this inhibition can also enhance the action of prostacyclin, which is produced by endothelial cells and has an anti-platelet effect. The overall result is a significant impact on hemostasis, making aspirin a common medication for preventing cardiovascular events, such as heart attacks and strokes.